Document is current

Article History

Received: 17 December 2025

Accepted: 30 June 2026

First Online: 9 July 2026

Declarations

:

: The study was conducted according to the guidelines of the Declaration of Helsinki. The protocol, amendments and informed consent documents were reviewed and approved by the Sterling Institutional Review Board (Sterling IRB), an independent ethics committee based in Atlanta, Georgia, USA (Protocol #C4591034). The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor, and followed generally accepted research practices described in Good Practices for Outcomes Research issued by the Professional Society for Health Economics and Outcomes Research [46] and Good Pharmacoepidemiology Practice [47]. Participation in the study was voluntary and anonymous. Consent was obtained from all subjects involved in the study electronically via the study’s E-Consent platform. Participants were informed that their de-identified survey responses would be used for research purposes and may be published and of their right to refuse or withdraw from the study at any time. Participants were compensated for their time.

: TH, AY, JCC, MBG, VLW, SMCL, and MDF, are employees of Pfizer and may hold stock or stock options of Pfizer. LLL, RB, and XS are employees of CVS Health, which received funding from Pfizer in connection with the development of this manuscript, and may hold stock or stock options of CVS Health.